SMPD1

SMPD1 Full Name

sphingomyelin phosphodiesterase 1, acid lysosomal

SMPD1 Introduction

Sphingomyelin phosphodiesterase 1 (SMPD1) encodes the vital enzyme known as acid sphingomyelinase (ASM), a member of the phosphodiesterase family primarily localized within the lysosomal compartment. As a zinc-dependent glycoprotein, ASM exists in two distinct forms derived from the same gene: a lysosomal form (L-ASM) and a secretory form (S-ASM). The fundamental physiological function of SMPD1 is to catalyze the hydrolysis of sphingomyelin into ceramide and phosphorylcholine. This reaction is a cornerstone of sphingolipid metabolism, maintaining the structural integrity of cellular membranes and regulating the "sphingolipid rheostat"—the balance between pro-survival sphingomyelin and the potent pro-apoptotic signaling molecule, ceramide. By modulating the biophysical properties of the plasma membrane, such as the formation of ceramide-rich platforms, SMPD1 acts as a master regulator of cellular responses to external stressors, including inflammation, infection, and ionizing radiation.

Figure 1. Release of acid sphingomyelinase (ASM) in the course of stress response and mode of action of its inhibition. (Source: Chung HY, et al. 2021)

The clinical significance of SMPD1 is most prominently illustrated by its association with Niemann-Pick Disease (NPD). Autosomal recessive mutations in the SMPD1 gene lead to a severe deficiency in ASM activity, resulting in the massive accumulation of undegraded sphingomyelin within lysosomes across various organs. This biochemical failure manifests as NPD types A and B. Type A is a devastating, neurodegenerative infantile disorder characterized by progressive neurological deterioration and hepatosplenomegaly, while Type B represents a milder, non-neuropathic phenotype with predominantly visceral involvement, such as pulmonary dysfunction and liver cirrhosis. Beyond these classical lysosomal storage disorders, emerging research has linked altered SMPD1 activity to a broader spectrum of systemic conditions. Elevated ASM levels are frequently observed in chronic inflammatory diseases, depression, and cardiovascular disorders, where over-activation of the ASM-ceramide pathway leads to membrane dysfunction and pathological cell signaling.

In the field of oncology, SMPD1 has emerged as a critical determinant of therapeutic efficacy. Ceramide generated by SMPD1 is essential for mediating the apoptotic effects of radiation and many chemotherapeutic agents. Consequently, many cancer cells attempt to downregulate or bypass SMPD1 activity to escape programmed cell death. Conversely, certain tumors exploit the secretory form of ASM to remodel the tumor microenvironment. Given its central role in both rare genetic disorders and common acquired diseases, SMPD1 is a high-value target for innovative therapies. Current clinical strategies include enzyme replacement therapy (ERT) for NPD patients and the development of small-molecule ASM inhibitors for treating depression and inflammation-related disorders. As precision medicine advances, SMPD1 remains a focal point for understanding the complex interplay between lipid metabolism and human health.

Alternate Names for SMPD1

SMPD1; sphingomyelin phosphodiesterase 1, acid lysosomal; ASM; NPD; ASMASE; sphingomyelin phosphodiesterase; acid sphingomyelinase;

• 1. Chung HY, et al. Keep Your Friends Close, but Your Enemies Closer: Role of Acid Sphingomyelinase During Infection and Host Response. Front Med (Lausanne). 2021 Jan 21;7:616500.
  2. Pfrieger FW. The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and cholesterol metabolism. Prog Lipid Res. 2023 Apr;90:101225.